Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended March 31, 2026 and unaudited Financial Results for the quarter ended March 31, 2026, along with the Auditor's report for the said period.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Sciences reported consolidated revenue of Rs. 1,368.98 Crores for FY26, up 6.6% from Rs. 1,283.76 Crores in FY25. However, the company posted a net loss of Rs. 7.41 Crores for the year compared to a profit of Rs. 0.54 Crores in the previous year. Q4 FY26 showed a profit of Rs. 9.60 Crores, recovering from a loss in Q3. The company has accumulated losses of Rs. 319.33 Crores and net current liabilities exceed current assets by Rs. 35.81 Crores. An exceptional item loss of Rs. 5.89 Crores was recorded due to gratuity impact under new labour codes. The statutory auditors Deloitte Haskins & Sells LLP issued an unmodified opinion. The company is raising additional funds through a rights issue, having collected Rs. 312.79 Crores out of Rs. 449.95 Crores target.
The company returned to profit in Q4 but recorded a full-year loss due to higher finance costs and exceptional items. The accumulated losses and working capital deficit raise going concern questions, though the rights issue and expected working capital renewal provide some mitigation. Shareholders should monitor the rights issue completion and revenue growth acceleration.